AR and prostate carcinoma: Reinforcing the report by Sharma et al. [103], a recent study shows that the pluripotency transcription factor Nanog homeobox (NANOG) alters FOXA1 and AR target genes during reprogramming of androgen-dependent prostate cancer cells to CRPC [122].